Evidence map›Paper›PMID 38178673›Full record

ArticleCurrent cancer drug targets2024

Naringenin-induced Oral Cancer Cell Apoptosis

YuYe Du, Jia Lai, Jingyao Su, Jiali Li, Chuqing Li, Bing Zhu, Yinghua Li

Abstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

YuYe DuDepartment of Kashan Outpatient Clinic, Affiliated Stomatology Hospital of Guangzhou Medical University, Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Guangzhou Key Laboratory of Basic and Applied Research of Oral Regenerative Medicine, Guangzhou, Guangdong, 510182, Chin.
Jia LaiCenter Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No 318 Renminzhong Road, Yuexiu District, Guangzhou, 510120, China.
Jingyao SuCenter Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No 318 Renminzhong Road, Yuexiu District, Guangzhou, 510120, China.
Jiali LiCenter Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No 318 Renminzhong Road, Yuexiu District, Guangzhou, 510120, China.
Chuqing LiCenter Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No 318 Renminzhong Road, Yuexiu District, Guangzhou, 510120, China.
Bing ZhuCenter Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No 318 Renminzhong Road, Yuexiu District, Guangzhou, 510120, China.
Yinghua LiCenter Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No 318 Renminzhong Road, Yuexiu District, Guangzhou, 510120, China.
Guangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral cancer is a malignant tumor with a high impact and poor prognosis. Naringenin, a flavonoid found in citrus fruits and its anti-inflammatory and antioxidant properties offer potential therapeutic benefits. However, limited studies have been conducted on the impact of naringenin on human tongue carcinoma CAL-27 cells. This study aims to elucidate the correlation between naringenin and tongue cancer, thereby identifying a potential therapeutic candidate for drug intervention against tongue cancer.

methodsThe effect of naringenin on the apoptosis of CAL-27 cells and its mechanism were studied by cell counting kit-8, mitochondrial membrane potential assay with JC-1, Annexin V-- FITC apoptosis detection, cell cycle, and apoptosis analysis, Reactive Oxygen Species assay and Western blot.

resultsThe results showed that naringenin significantly induced apoptosis in CAL-27 cells in a dose-dependent manner. Mechanistically, naringenin-induced apoptosis was mediated through the upregulation of Bid and downregulation of Bcl-xl, which led to increased generation of ROS.

conclusionThe findings suggested that naringenin may represent a promising candidate for the treatment of oral cancer by inducing apoptotic cell death via modulation of the Bid and Bcl-xl signaling pathways.

Indexed as

Apoptosisbcl-X ProteinBH3 Interacting Domain Death Agonist ProteinFlavanonesReactive Oxygen SpeciesSignal TransductionCell Line, TumorCell ProliferationHumansMembrane Potential, MitochondrialMouth NeoplasmsTongue NeoplasmsBCL2L1 protein, humanbcl-X ProteinBH3 Interacting Domain Death Agonist ProteinBID protein, humanFlavanonesnaringeninReactive Oxygen Speciesapoptosis.Bcl-xlBidNaringeninoral cancerROSsignaling pathway

Identifiers

PMID38178673
OpenAlexW4389207196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.